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Abstract 
Keloidal atypical fibroxanthoma (KAF) has recently been categorized as a variant of atypical 
fibroxanthoma. This paper will emphasize the importance of including KAF in both clinical 
and histological differential diagnosis of benign and malignant lesions which exhibit keloidal 
collagen and will also review the current literature on epidemiology, pathogenesis, histology, 
immunochemistry and treatments.  © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Atypical fibroxanthoma (AFX) is an asymptomatic low-grade sarcoma that was first de-
scribed by Helwig [1] in 1961.  
Numerous histological variants of AFX have been described, including clear cell [2–4], 
granular cell [5–7], chondroid [8], hemosiderin pigmented [9], osteoid [10] AFX with osteo-
clast-like giant cells [11, 12] and sclerotic forms [13]. Keloidal AFX (KAF) is a recently de-
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scribed variant that has often been misdiagnosed [14]. KAF was first mentioned in the study 
by Welsh [15] in 2006. KAF is a variant of AFX that consists of thick bands of hyalinized  
keloid-like collagen [16].  
Case Report 
We present a 75-year-old Caucasian male with a 1.3-cm pink-to-brown dome-shaped 
nodule on the helix of the left ear. A shave biopsy was performed, which demonstrated a 
cytologically malignant spindle cell neoplasm diffusely replacing the dermis and involving 
the biopsy margins. The spindle cells revealed enlarged and hyperchromatic nuclei with 
prominent nucleoli and irregular nuclear contours arranged in vaguely intersecting fascicles 
which effaced the dermal-epidermal junction. A scant chronic inflammatory cell infiltrate 
was present which was admixed with the tumor cells. Scattered multinucleated bizarre tu-
mor cells, as well as scattered atypical mitotic figures, were noted. A sclerotic background 
with hyalinized keloidal-like collagen bundles was admixed with the proliferation of spindle 
cells. The spindle cells were positive for CD68 and negative for S100, Melan-A, pancyto-
keratin, smooth muscle actin (SMA) and p63. Ki-67 showed a high proliferation rate labeling 
40% of tumor cells. 
The second case is a 69-year-old male who presented with an atypical lesion on his right 
ear. A shave biopsy also demonstrated a cytologically malignant spindle cell neoplasm, with 
diffuse replacement by malignant spindle cells. The spindle cells demonstrated a marked 
degree of pleomorphism with hyperchromatic and enlarged nuclei with prominent nucleoli 
and scattered bizarre multinucleated giant cells. A prominent sclerotic component was pres-
ent with a hyalinized keloid-like collagen bundle. Scattered chronic inflammation was noted 
in the background. Immunohistochemical studies were performed on the spindle cells, and 
the results were as follows: positive for CD10, factor XIIIa, SMA (60% staining) and CD68 
focally positive. The spindle cells were negative for S100 and cytokeratin. 
The immunohistochemical findings of both of these lesions combined with the morphol-
ogy of the tumors are consistent with a new variant of AFX known as ‘keloidal atypical fi-
broxanthoma’. Immunostaining was performed to exclude other pathologies, such as leio-
myosarcoma, sarcomatoid carcinoma or spindle cell melanoma.  
KAF is a new, recent variant of AFX that was first described in 2006 [15]. It is clinically 
and histologically similar to a variety of pathologies. Dermatologists and dermato-
pathologists need to include KAF in their differential diagnosis of keloidal scarring lesions. 
Additionally, our goal is to further acknowledge this variant of AFX and to advocate for this 
variant to become more officially accepted in the literature. We feel that recognition of KAF 
represents an important step in distinguishing between benign and malignant lesions which 
exhibit keloidal collagen, including keloidal dermatofibroma (KDF), leiomyosarcoma, fibro-
sarcoma and fibromatosis (fig. 1, fig. 2, fig. 3, fig. 4). 
Differential Diagnosis 
To diagnose KAF, other benign and malignant lesions with keloidal collagen must be ex-
cluded, such as KDF, leiomyosarcoma, fibrosarcoma and fibromatosis. The clinical differen-
tial diagnosis of 9 cases of KAF in the study of Kim and McNiff [16] included basal cell carci-
noma (5 cases), squamous cell carcinoma (SCC; 4 cases), melanoma (1 case), angioma (1 
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case) and actinic keratosis (1 case). There are also case reports on keloidal collagen histolog-
ically presenting as other benign and malignant lesions including basal cell carcinomas [17, 
18], sclerotic nevi [19], Spitz nevi, solitary fibrous tumor, scleroderma, sclerotic nevi and 
histiocytoma [17, 19–23].  
Histology and Immunohistochemistry 
Diagnosis of KAF is made based on histological findings and immunohistochemistry. 
Histologically, it is characterized by a thin atrophic epidermis and a storiform proliferation 
of large fibrocystic [24], atypical spindle-shaped cells with moderate amounts of cytoplasm 
and large atypical neoplastic cells with abundant pale-staining vacuolated cytoplasm. The 
neoplastic cells are bizarre, large, round polyhedral, and are multinucleated giant cells with 
hyperchromatic nuclei. Numerous atypical mitotic figures are present within the keloidal 
sclerotic collagen [25]. Sometimes ulceration may be present [4]. KAF may also have vascu-
lar proliferation in the superficial portion of the tumor [16]. A small amount of coarse, glassy 
eosinophilic, keloid-like collagen fibers may be present in AFX. However, histologically, KAF 
has thick bands of hyalinized collagen/keloidal fibers prominent in the dermis admixed with 
pleomorphic, atypical and multinucleated cells [16, 25]. The keloidal collagen can present in 
an interstitial pattern and focally form ring-like structures that preferentially deposit around 
small vessels which can be demonstrated by CD31 immunostaining [14, 16]. Bland hypocel-
lular sclerosis replacing >50% of the tumor may represent a sclerotic variant of AFX [14]. In 
our case, sclerosis was present but did not replace >50% of the tumor. 
The immunohistochemical profile of KAF is similar to that of AFX. AFX is chiefly defined 
by a diagnosis of exclusion, but there are several markers that can be used to help making an 
accurate diagnosis. The summary provided in table 1 can be used in this respect. AFX ex-
presses CD68 [26, 27], CD10 [26], vimentin, α1-antitypsin, 1-antichymotrypsin, CD99 [29, 
30], CD74 and CD163 [31]. The presence of CD74 (LN-2 antibody) has been proposed to 
indicate more aggressive behavior. AFX needs to be differentiated from spindle cell SCC and 
desmoplastic melanoma [4]. S100 is positive in desmoplastic melanoma and negative in AFX 
[2, 32, 33]. Cytokeratin, p63, high- and low-molecular-weight keratin are positive in spindle 
cell SCC and negative in AFX [34, 35]. KAF will have identical immunohistochemistry find-
ings with AFX, with the histological description given above.  
Other benign and malignant lesions which histologically resemble KAF must also be ex-
cluded. These are KDF, cutaneous leiomyosarcoma, fibromatosis and fibrosarcoma. KDF is a 
variant of dermatofibroma characterized by the presence of keloidal collagen in a typical 
dermatofibroma [36]. Within the keloid collagen, multinucleated giant cells, hemorrhage, 
hemosiderin deposits and scattered KiM1P-positive histiocytes are present. However, factor 
XIIIa- or CD34-positive cells and S100 are absent. Factor XIIIa-positive dendrocytes are pres-
ent in the surrounding areas where keloidal collagen is not present. Histiocytic markers KP1 
(CD68), KiM1P, Mac387 and vimentin are present in the keloidal areas and the surrounding 
dermatofibroma areas [20]. Also, in all of these benign entities, the cytological blandness and 
general paucity of mitotic figures helps to differentiate from KAF. 
There are many case reports which demonstrate that leiomyosarcomas have mistakenly 
been diagnosed as keloids [37–39]. Leiomyosarcomas present with a fascicular arrangement 
of hyperchromatic spindle cells and atypical mitotic figures. Immunohistochemical studies 
are positive for actin, desmin and vimentin and negative for S100. SMA and keratin are not 
consistently expressed [40]. Fibrosarcomas demonstrate atypical fibroblasts and collagen 
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with proliferation of atypical spindle-shaped cells arranged as intersecting fascicles in a her-
ringbone growth pattern. High-grade fibrosarcomas may be positive for vimentin and actin 
[41]. Fibromatosis lesions are composed of long-sweeping fascicles of bland fibroblast in a 
collagenous stromal background. Atypical mitotic features are absent. Lesions are positive 
for vimentin and negative for S100 and desmin [42]. Scars are typically negative for CD34, 
factor XIIIa and S100 [43]. To distinguish KAF from a keloid or scar, Ki-67 staining will 
demonstrate a high proliferation rate as evidenced by our case.  
Discussion 
Kim and McNiff [16] were the first authors to write an article on KAF, where they ana-
lyzed 9 cases of AFX with keloidal tumoral sclerosis. Histology demonstrated pleomorphic 
tumor cells within hyalinized keloidal collagen bands. Some cases revealed keloidal collagen-
forming ring-shaped structures around CD31-positive vascular structures. Their study indi-
cates that pleomorphic cells were negative for the S100 protein and cytokeratin, but all cases 
were positive for antibodies targeted towards CD68. The average age of patients in their 
study was 80 years and ranged from 66 to 91 years. Seven were males and 2 were females, 
with all lesions originating from the head and neck. Histologically, their studies demonstrat-
ed atrophic epidermis, confirmed in 2 out of 9 cases. The tumors contained both spindle and 
pleomorphic cells with atypical mitosis, admixed within keloidal collagen. CD31 staining 
demonstrated the keloidal collagen deposition around small vessels in a ring-like fashion 
within the tumor, in addition to being present in an interstitial pattern. This is the first case 
of keloidal collagen being deposited preferentially around vascular structures and focally at 
the basement membrane in AFX. Keloidal collagen deposition in this fashion is not specific to 
KAF [16].  
Stefanato et al. [44] studied 8 cases of AFX in order to analyze tumor architecture, de-
gree of pattern of fibrosis and inflammatory cell infiltrate. Three of 8 cases exhibited a ke-
loidal variant without any specific pattern. The KAF observed in this study had changed only 
focally and did not reveal the perivascular deposition of keloidal collagen that was observed 
in the study of Kim and McNiff [16]. However, all 8 cases, which included other variants of 
AFX, did present a sclerotic stroma similar to the cases in our study.  
Offman et al. [14] analyzed 91 cases of AFX which were diagnosed in their institution 
over a 10-year period, and 17 (19%) of them were identified as KAF. Their study suggested 
that collagen is a product of tumor cells and not part of a stromal response to the lesion, 
supporting the purported fibrohistiocytic or myofibroblastic lineage of AFX. They concluded 
that the presence of keloidal collagen does not promote involution of AFX. There was no 
difference in demographic data from patients who had KAF compared to other variants of 
AFX. Their cases displayed keloidal collagen dispersed between tumor cells, as well as simi-
lar collagen in thinner strands encircling the vessels. These authors indicated that there is 
some morphological overlap between the keloidal variant of AFX and the sclerotic variant. 
This is further supported by Bruecks et al. [13] with their report on sclerosis and hyaliniza-
tion. Similarly, both of our cases had also revealed sclerosis. 
Wide local excision with frozen section control or Mohs micrographic surgery is the 
treatment of choice for AFX. When AFX is diagnosed, the potential for metastasis should 
always be considered [4]. Due to the possibility of local recurrence and a spread to the 
lymph nodes, complete tumor removal is required [45–49].  
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Conclusion 
KAF may be confused with benign and malignant lesions which exhibit keloidal collagen. 
The 2 cases we present fit within the clinical and histopathological profile of previously re-
ported cases. They demonstrate that keloidal collagen may be present in AFX lesions estab-
lishing a variant of the classical histopathological presentation. Histologically, both our cases 
presented with a sclerotic background with hyalinized keloid-like collagen bundles admixed 
with the proliferation of spindle cells. Our case and the few previously reported cases repre-
sent a distinct and under-recognized variant of AFX which may be misdiagnosed as KDF, 
leiomyosarcoma, fibrosarcoma, fibromatosis scars, spindle cell SCC and desmoplastic mela-
noma. The accurate diagnosis of KAF differentiating it from other keloidal lesions can be 
accomplished through conventional histopathology and immunohistochemical markers. 
Nevertheless, the cases described herein emphasize the importance of diagnosing KAF and 
differentiating it from other malignant and benign lesions with keloidal collagen. Dermatolo-
gists and dermatopathologists should be aware of this variant to avoid improper diagnoses. 
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Fig. 1. Hematoxylin and eosin. ×2.5. 
 
 
 
Fig. 2. Hematoxylin and eosin. ×5. 
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Fig. 3. Hematoxylin and eosin. ×10. 
 
 
 
Fig. 4. Hematoxylin and eosin. ×20. 
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Table 1. Immunohistochemical markers 
        
        Immunohistochemistry KAF/ 
AFX 
Spindle 
cell SCC 
Desmo-
plastic  
melano-
ma 
KDF Leiomyo-
sarcoma 
Fibrosar-
coma 
Fibroma-
tosis 
        
        
α1-Antitypsin √       
1-Antichymotrypsin √       
Vimentin √ √ √  √ √ √ 
S100   √     
Neuron-specific enolase   √     
CD68 √   √    
Microphthalmia transcription factor   √     
Melanoma cell adhesion molecule   √     
CD10 √ √ √     
p63  √      
Cytokeratin  √      
LN-2 (CD74) √       
CD99 √       
KiM1P    √    
MAC387    √    
Actin √    √ √  
Desmin     √   
        
        
 
